Welcome to our dedicated page for Heska news (Ticker: HSKA), a resource for investors and traders seeking the latest updates and insights on Heska stock.
Heska Corporation (NASDAQ: HSKA) delivers innovative veterinary diagnostic and imaging solutions to advance animal healthcare worldwide. This dedicated news hub provides investors and veterinary professionals with timely updates on Heska's strategic developments, technological breakthroughs, and market positioning.
Key Resources Include: Official announcements of new product releases, financial performance updates, partnership disclosures, and regulatory milestones. Track Heska's progress in diagnostic systems, imaging technologies, and allergy/renal health solutions through verified primary sources.
Stay Informed On: Earnings call details, acquisition activity, research collaborations like the Dalan Animal Health partnership, and enhancements to Heska's Cuattro imaging platform. This centralized repository eliminates the need to monitor multiple channels for critical updates.
Bookmark this page for efficient tracking of Heska's contributions to veterinary medicine and their impact on the animal health sector. Check regularly for unfiltered access to the company's latest advancements in pet care technology.
Heska Corporation (NASDAQ: HSKA) has announced its 2023 Annual Meeting of Stockholders, scheduled for May 3, 2023, at 9 a.m. MT / 11 a.m. ET. Stockholders of record as of March 6, 2023, are entitled to participate and vote at the meeting. The company encourages stockholders to vote by proxy on the proposed matters before the meeting. Heska is a provider of advanced veterinary diagnostic and specialty solutions, focusing on point-of-care diagnostic products and related services. The company operates in two segments: North America and International, with products aimed at supporting companion animal veterinarians. Stockholders can access the meeting via a webcast link provided in the announcement.
Mars, Incorporated announced a definitive agreement to acquire Heska Corporation (NASDAQ: HSKA) for $120.00 per share, reflecting a 38% premium over the 60-day average share price and a 23% premium on the closing price as of March 31, 2023. The acquisition, unanimously approved by both boards, aims to enhance diagnostics and technology access for veterinary professionals and pets. Upon closing, expected in the second half of 2023, Heska will become part of Mars Petcare, expanding its Science & Diagnostics division. The transaction is subject to customary closing conditions, including shareholder and regulatory approvals.
Heska Corporation (NASDAQ: HSKA) reported its financial results for Q4 and the full year ending December 31, 2022, showing consolidated revenue of $257.3 million, up 1.4% year-over-year. Key achievements include an increase in North America lab consumables sales by 8.7% and total active subscriptions rising 18%. The full-year gross margin improved to 43.2%, a 150 basis points year-over-year increase. Despite a net loss of $19.9 million for the year, the company anticipates revenue growth between 8%-12% in 2023, driven by anticipated 12%-15% growth in POC lab consumables.
Heska Corporation (NASDAQ: HSKA), a leader in advanced veterinary diagnostics, announced its participation in three institutional investor conferences in March 2023. Key events include the Bank of America Securities Animal Health Summit on March 2, where CEO Kevin Wilson will engage in a virtual fireside chat. The Raymond James Annual Institutional Investors Conference on March 7 will feature Mr. Wilson presenting followed by a Q&A session. Lastly, CFO Catherine Grassman will participate in the Barclays Global Healthcare Conference on March 14. All sessions will have access to webcasts via Heska's Investor Relations website.
Heska Corporation (NASDAQ: HSKA) will release its fourth quarter and full year 2022 financial results before market open on February 28, 2023. An earnings call is scheduled for 9 a.m. MT (11 a.m. ET) to discuss these results. Investors can access the call via telephone or through a live webcast on the company's investor relations website. A replay of the call will be available from 2 p.m. ET on the same day until March 14, 2023. Heska specializes in advanced veterinary diagnostic and specialty solutions, serving companion animal veterinarians across North America and internationally.
Dalan Animal Health announced that the USDA has granted a conditional license for a vaccine to protect honeybees from American Foulbrood disease, a major threat to agriculture. This vaccine is a major advancement, as it enables prevention rather than the previous method of euthanizing infected hives. Developed by Dalan and manufactured by Diamond Animal Health, the non-GMO vaccine is anticipated to be on the market in 2023. This innovation aims to enhance honeybee health and secure global food production, as honeybees are crucial for pollination.
